Clinical trial · Interventional
A Study of Vantictumab (OMP-18R5) in Combination With Nab-Paclitaxel and Gemcitabine in Previously Untreated Stage IV Pancreatic Cancer
A Phase 1b Dose Escalation Study of Vantictumab (OMP-18R5) in Combination With Nab-Paclitaxel and Gemcitabine in Patients With Previously Untreated Stage IV Pancreatic Cancer
NCT02005315CI-TRIAL-00047024completedPhase 1ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This is an open-label Phase 1b dose-escalation study to assess the safety, tolerability, and PK of vantictumab when combined with nab-paclitaxel and gemcitabine.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Pancreatic Cancer | Malignant Pancreatic Neoplasm | CURATED_EXACT | 0.92 |
| Stage IV Pancreatic Cancer | Malignant Pancreatic Neoplasm | CURATED_BROADER | 0.78 |
Interventions
Interventions (3)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Gemcitabine | Drug | Gemcitabine | ALIAS |
| Nab-Paclitaxel | Drug | Nab-paclitaxel | ALIAS |
| Vantictumab | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (3)
- type
- EXPERIMENTAL
- label
- Vanctictumab (OMP-18R5)
- description
- Vantictumab will be administered by intravenous (IV) infusion.
- interventionNames
- Drug: Vantictumab
- Drug: Nab-Paclitaxel
- Drug: Gemcitabine
- type
- EXPERIMENTAL
- label
- Nab-Paclitaxel
- description
- Nab-Paclitaxel will be administered by intravenous (IV) infusion.
- interventionNames
- Drug: Vantictumab
- Drug: Nab-Paclitaxel
- Drug: Gemcitabine
- type
- EXPERIMENTAL
- label
- Gemcitabine
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 90 Years
Show eligibility criteria text
Inclusion Criteria: * Signed Informed Consent Form * Age ≥18 years * Histologically documented Stage IV ductal adenocarcinoma of the pancreas * Availability of tumor tissue, either archival FFPE or obtained at study entry through fresh biopsy * ECOG performance status of 0 or 1 * Adequate hematologic and end-organ function * Evaluable or measurable disease per RECIST v1.1 * For women of childbearing potential and men with partners of childbearing potential, agreement to use two effective forms of contraception Exclusion Criteria: * Prior therapy before Day 1 of Cycle 1 for the treatment of Stage IV pancreatic cancer * Prior adjuvant therapy for the treatment of ductal adenocarcinoma of the pancreas * Known hypersensitivity to any component of study treatments * Known brain metastases, uncontrolled seizure disorder, or active neurologic disease
References
Publications (0)
Data not yet available
No reference posted for this study.